: AstraZeneca’s new COVID-19 vaccine trial data will give the shot a U.S. boost


The COVID-19 vaccine of the U.K.-Swedish pharmaceuticals group AstraZeneca, developed with the University of Oxford, has shown robust results in its U.S. trial, the company said on Monday, with 79% efficacy at preventing symptoms and 100% efficacy against severe or critical disease and hospitalization.

  • The news paves the way for the vaccine to be submitted to the U.S. regulator.
  • The vaccine, currently the cheapest and most used in the world, was authorized three months ago by the U.K. and European Union medicines watchdogs.
  • U.S. facilities have already made or are in the process of manufacturing an estimated 30-to-40 million doses of the shot. Washington agreed last week to send some 4 million doses to Canada and Mexico.
  • The AstraZeneca

    vaccine was briefly suspended last week for a few days in most of Europe on safety concerns, until both the U.K. and EU regulators insisted after new reviews that it remains safe.

Read: AstraZeneca Vaccine Found to Be Safe and 79% Effective in U.S. Trial. The Stock Is Rising.

The outlook: The U.S. has already embarked on a massive vaccination campaign using other shots, with more than 37% of the population having been injected with one of the available vaccines.

So the AstraZeneca shot won’t play the same role there that it does in the rest of the world. But the results of the trial may help restore its reputation further, after last week’s renewed greenlights from the EU authorities.

Read: Israel Is a Vaccine Leader. Now Its Economy Is Improving.

Economic Report: U.S. economy contracted in February, Chicago Fed index shows

Previous article

Outside the Box: I’m 73, single and work part time, should I put money into an IRA?

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News